BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

M. Wilhelm, Scott; Carter, Christopher; Tang, LiYa; Wilkie, Dean; McNabola, Angela; Rong, Hong; Chen, Charles; Zhang, Xiaomei; W. Vincent, Patrick; McHugh, Mark; Cao, Yichen; Shujath, Jaleel; L. Gawlak, Susan; Eveleigh, Deepa; R. Rowley, Bruce; Liu, Li; Adnane, Lila; Lynch, Mark; Auclair, Daniel; Taylor, I; Gedrich, Rich; Voznesensky, Andrei; Riedl, Bernd; Post, Leonard; Bollag, Gideon; A. Trail, Pamela

doi:10.1158/0008-5472.can-04-1443

Public

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Published in Cancer Research • Oct 1, 2004

Authors:

Scott M. Wilhelm

Christopher Carter

LiYa Tang

Abstract

The RAS/RAF signaling pathway is an important mediator of tumor cell proliferation and angiogenesis. The novel bi-aryl urea BAY 43-9006 is a potent inhibitor of Raf-1, a member of the RAF/MEK/ERK signaling pathway. Additional characterization showed that BAY 43-9006 suppresses both wild-type and V59...

Subject

Cancer research

Receptor tyrosine kinase

MAPK/ERK pathway

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!